目的:探讨Ki-67蛋白在弥漫大B细胞淋巴瘤(DLBCL)组织中的表达情况及其对患者预后的意义。方法:采用EliVision plus免疫组织化学二步法测定85例DLBCL患者肿瘤组织中Ki-67蛋白的表达,前瞻性调查分析其与临床特征及疗效的关系。结果:85例DLBCL患者中36例(42.4%)肿瘤组织呈Ki-67蛋白高表达。Non-GCB组Ki-67高表达率为56.1%,GCB组Ki-67高表达率为29.5%,差异有统计学意义(P<0.05)。中位随访24个月后,生存分析显示Ki-67高表达组中位疾病无进展生存时间(PFS)为18个月,短于Ki-67低表达组31个月,两组PFS差异有统计学意义(P<0.05)。Ki-67高表达组接受R-CHOP方案化疗PFS长于CHOP方案组,差异有统计学意义(P<0.05),在Ki-67低表达组未观察到两种化疗方案PFS差异有统计学意义(P>0.05)。结论:Ki-67对判断弥漫大B细胞淋巴瘤预后及选择治疗方案均有较好的指导意义。 Objective: To investigate the expression of Ki-67 in diffuse large B cell lymphoma (DLBCL) and its significance to the prognosis of patients. Methods: The expression of Ki-67 protein in 85 cases of DLBCL was detected by EliVision plus immunohistochemical two-step method. The relationship between Ki-67 protein and clinical features and therapeutic effect was prospectively analyzed. Results: Thirty-six cases (42.4%) of 85 DLBCL patients had high expression of Ki-67 protein. The positive rate of Ki-67 expression in Non-GCB group was 56.1%, while that in GCB group was 29.5%. The difference was statistically significant (P <0.05). After a median follow-up of 24 months, the survival analysis showed that the median progression-free survival time (PFS) was 18 months in the Ki-67 overexpression group, which was shorter than that in the Ki-67 overexpression group for 31 months Significance (P <0.05). The PFS of Ki-67 overexpression group receiving R-CHOP regimen was longer than that of CHOP regimen group (P <0.05), but there was no significant difference between the two chemotherapy regimens in Ki-67 overexpression group (P <0.05) P> 0.05). Conclusion: Ki-67 has a good guiding significance for the prognosis and treatment of diffuse large B-cell lymphoma.